Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments:
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factor
3.2.2 Top winning strategies
3.2.3 Top investment pockets

3.3 Porters five forces analysis

3.3.1 Low bargaining power of suppliers due to large number of suppliers and moderate switching cost
3.3.2 Moderate bargaining power of buyers due to large number of buyers, high product dependency and moderate switching cost.
3.3.3 Moderate threat of substitutes due to ease of substitution, moderate price war and high brand loyalty
3.3.4 Low threat of new entrants due to presence of dominant players and high investment cost and legal barriers
3.3.5 Presence of numerous players, high growth rate and high economic base increases the competition among rivalries

3.4 Drivers

3.4.1 Effective solution for the healthy embryos
3.4.2 Increasing infertility rate and genetic, hereditary and chromosomal diseases
3.4.3 Innovative and wide range of applications such as development of savior siblings and gender selection among others

3.5 Restraints

3.5.1 Stringent regulations and ethical concerns
3.5.2 High cost incurred and risk involved in PGD

3.6 Opportunities

3.6.1 Increasing adoption of PGD in developing countries

Chapter: 4 WORLD PGD MARKET, BY TEST TYPE

4.1 Introduction
4.2 Chromosomal Abnormalities

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 North America Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.5 Europe Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.6 Asia Pacific Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.7 LAMEA Chromosomal Abnormalities Market, Growth (%) 2014-2022

4.3 Aneuploidy

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 North America Aneuploidy Market, Growth (%) 2014-2022
4.3.5 Europe Aneuploidy Market, Growth (%) 2014-2022
4.3.6 Asia Pacific Aneuploidy Market, Growth (%) 2014-2022
4.3.7 LAMEA Aneuploidy Market, Growth (%) 2014-2022

4.4 X-linked Diseases

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 North America X-Linked Diseases Market, Growth (%) 2014-2022
4.4.5 Europe X-Linked Diseases Market, Growth (%) 2014-2022
4.4.6 Asia Pacific X-Linked Diseases Market, Growth (%) 2014-2022
4.4.7 LAMEA X-Linked Diseases Market, Growth (%) 2014-2022

4.5 Single Gene Disorders

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast
4.5.4 North America Single Gene Disorders Market, Growth (%) 2014-2022
4.5.5 Europe Single Gene Disorders Market, Growth (%) 2014-2022
4.5.6 Asia Pacific Single Gene Disorders Market, Growth (%) 2014-2022
4.5.7 LAMEA Single Gene Disorders Market, Growth (%) 2014-2022

4.6 HLA Typing

4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast
4.6.4 North America HLA Typing Market, Growth (%) 2014-2022
4.6.5 Europe HLA Typing Market, Growth (%) 2014-2022
4.6.6 Asia Pacific HLA Typing Market, Growth (%) 2014-2022
4.6.7 LAMEA HLA Typing Market, Growth (%) 2014-2022

4.7 Gender selection

4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast
4.7.4 North America Gender Selection Market, Growth (%) 2014-2022
4.7.5 Europe Gender Selection Market, Growth (%) 2014-2022
4.7.6 Asia Pacific Gender Selection Market, Growth (%) 2014-2022
4.7.7 LAMEA Gender Selection Market, Growth (%) 2014-2022

4.8 Others PGD Test (Disability and Adult Onset Disease)

4.8.1 Key market trends
4.8.2 Key growth factors and opportunities
4.8.3 Market size and forecast
4.8.4 North America Others PGD Market, Growth (%) 2014-2022
4.8.5 Europe Others PGD Market, Growth (%) 2014-2022
4.8.6 Asia Pacific Others PGD Market, Growth (%) 2014-2022
4.8.7 LAMEA Others PGD Market, Growth (%) 2014-2022

Chapter: 5 WORLD PGD MARKET, BY GEOGRAPHY

5.1 Introduction
5.2 North America

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast

5.3 Europe

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 Asia Pacific (APAC)

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast

5.5 LAMEA

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

Chapter: 6 COMPANY PROFILE

6.1 Reprogenetics, LLC.

6.1.1 Company Snapshot
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategies & developments

6.2 F. Hoffmann-La Roche AG

6.2.1 Company Snapshot
6.2.2 Operating business segments
6.2.3 Business performance
6.2.4 Key strategies & developments

6.3 Genea Limited

6.3.1 Company overview
6.3.2 Company Snapshot
6.3.3 Operating business segments
6.3.4 Business performance
6.3.5 Key strategies & developments

6.4 Illumina, Inc

6.4.1 Company overview
6.4.2 Company Snapshot
6.4.3 Operating business segments
6.4.4 Business performance
6.4.5 Key strategies & developments

6.5 Laboratory Corporation of America Holdings

6.5.1 Company overview
6.5.2 Company Snapshot
6.5.3 Operating business segments
6.5.4 Business performance
6.5.5 Key strategies & developments

6.6 Natera, Inc

6.6.1 Company overview
6.6.2 Company Snapshot
6.6.3 Operating business segments
6.6.4 Business performance
6.6.5 Key strategies & developments

6.7 PerkinElmer, Inc

6.7.1 Company overview
6.7.2 Company Snapshot
6.7.3 Operating business segments
6.7.4 Business performance
6.7.5 Key strategies & developments

6.8 Genesis Genetics Ltd

6.8.1 Company overview
6.8.2 Company Snapshot
6.8.3 Operating business segments
6.8.4 Business performance
6.8.5 Key strategies & developments

6.9 Reproductive Genetics Innovations LLC.

6.9.1 Company overview
6.9.2 Company Snapshot
6.9.3 Operating business segments
6.9.4 Business performance
6.9.5 Key strategies & developments

6.10 Quest Diagnostics Inc.

6.10.1 Company overview
6.10.2 Company Snapshot
6.10.3 Operating business segments
6.10.4 Business performance
6.10.5 Key strategies & developments